Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
AIDS and Behavior
Published in: AIDS and Behavior 7/2011

01-10-2011 | Original Paper

Changes in the Prevalence of Injection Drug Use Among Adolescents and Young Adults in Large U.S. Metropolitan Areas

Authors: Sudip Chatterjee, Barbara Tempalski, Enrique R. Pouget, Hannah L. F. Cooper, Charles M. Cleland, Samuel R. Friedman

Published in: AIDS and Behavior | Issue 7/2011

Login to get access

Abstract

Young injection drug users (IDUs) are at risk for acquiring blood-borne diseases like HIV and Hepatitis C. Little is known about the population prevalence of young IDUs. We (1) estimate annual population prevalence rates of young IDUs (aged 15–29) per 10,000 in 95 large U.S. metropolitan statistical areas (MSAs) from 1992 to 2002; (2) assess the validity of these estimates; and (3) explore whether injection drug use among youth in these MSAs began to rise after HAART was discovered. A linear mixed model (LMM) estimated the annual population prevalence of young IDUs in each MSA and described trends therein. The population prevalence of IDUs among youths across 95 MSAs increased from 1996 (mean = 95.64) to 2002 (mean = 115.59). Additional analyses of the proportion of young IDUs using health services suggest this increase may have continued after 2002. Harm reduction and prevention research and programs for young IDUs are needed.
Appendix
Available only for authorised users
Footnotes
1
For each data series, cells were defined by year and MSA; 11 years × 95 MSAs = 1,045 cells.
 
Literature
1.
Miller CL, Spittal PM, LaLiberte N, Li K, Tyndall MW, O’Shaughnessy MV, Schechter MT. Females experiencing sexual and drug vulnerabilities are at elevated risk for HIV infection among youth who use injection drugs. J Acquir Immune Defic Syndr. 2002;30:335–41.PubMed
2.
Miller CL, Tyndall M, Spittal P, Li K, LaLiberte N, Schechter MT. HIV incidence and associated risk factors among young injection drug users. AIDS. 2002;16:491–3.PubMedCrossRef
3.
Fennema JS, Van Ameijden EJ, Van Den Hoek A, Coutinho RA. Young and recent-onset injecting drug users are at higher risk for HIV. Addiction. 1997;92:1457–65.PubMedCrossRef
4.
Doherty MC, Garfein RS, Monterroso E, Brown D, Vlahov D. Correlates of HIV infection among young adult short-term injection drug users. AIDS. 2000;14:717–26.PubMedCrossRef
5.
Judd A, Hickman M, Jones S, McDonald T, Parry JV, Stimson JV, Hall AJ. Incidence of hepatitis C virus and HIV among new injecting drug users in London: prospective cohort study. BMJ. 2005;330:24–5.PubMedCrossRef
6.
Hahn JA, Page-Shafer K, Lum PJ, Bourgois P, Stein E, Evans JL, Busch MP, Tobler LH, Phelps B, Moss AR. Hepatitis C virus seroconversion among young injection drug users: relationships and risks. J Infect Dis. 2002;186:1558–64.PubMedCrossRef
7.
Des Jarlais DC, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M, Rockwell R, Edwards V, Friedman SR, Monterroso E, Williams I, Garfein R. Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003;157:467–71.PubMedCrossRef
8.
Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health. 2001;91(1):42–6.PubMed
9.
Garfein RS, Doherty MC, Monterroso ER, Thomas DL, Nelson KE, Vlahov D. Prevalence and incidence of hepatitis C virus infection among young adult injection drug users. J Acquir Immune Defic Syndr Hum Retrovir. 1998;18(Suppl 1):S11–9.
10.
Hahn JA, Page-Shafer K, Lum PJ, Ochoa K, Moss AR. Hepatitis C virus infection and needle exchange use among young injection drug users in San Francisco. Hepatology. 2001;34:180–7.PubMedCrossRef
11.
Kral AH, Lorvick J, Edlin BR. Sex- and drug-related risk among populations of younger and older injection drug users in adjacent neighborhoods in San Francisco. J Acquir Immune Defic Syndr. 2000;24:162–7.PubMedCrossRef
12.
Thorpe L, Ouellet L, Levy J, Williams I, Monterroso E. Hepatitis C virus infection: prevalence, risk factors, and prevention opportunities among young injection drug users in Chicago, 1997–1999. J Infect Dis. 2000;182:1588–94.PubMedCrossRef
13.
Ochoa KC, Hahn JA, Seal KH, Moss AR. Overdosing among young injection drug users in San Francisco. Addict Behav. 2001;26:453–60.PubMedCrossRef
14.
Cooper HLF, Brady JE, Friedman SR, Tempalski B, Gostnell K, Flom PL. Estimating the prevalence of injection drug use among Black and White adults in large U.S. metropolitan areas over time (1992–2002): estimation methods and prevalence trends. J Urban Health. 2008;85:826–56.PubMedCrossRef
15.
Wright D, Gfroerer J, Epstein J. The use of external data sources and ratio estimation to improve estimates of hardcore drug use from the NHSDA. NIDA research monograph, vol. 167. Rockville: Office of Applied Studies, Substance Abuse and Mental Health Services Administration; 1997.
16.
Wright D, Gfroerer J, Epstein J. Ratio estimation of hardcore drug use. J Off Stat. 1997;13:401–16.
17.
Archibald CP, Jayaraman GC, Major C, Patrick DM, Houston SM, Sutherland D. Estimating the size of hard-to-reach populations: a novel method using HIV testing data compared to other methods. AIDS. 2001;15(Suppl 3):S41–8.PubMedCrossRef
18.
Korf D, Reijneveld S, Toet J. Estimating the number of heroin users: a review of methods and empirical findings from the Netherlands. Int J Addict. 1994;29:1393–417.PubMed
19.
Galea S, Nandi A, Vlahov D. The social epidemiology of substance use. Epidemiol Rev. 2004;26:36–52.PubMedCrossRef
20.
Friedman SR, Pouget ER, Chatterjee S, Cleland CM, Tempalski B, Brady JE, Cooper HLF. Do drug arrest deter drug use? Am J Public Health. 2011;101:344–9.PubMedCrossRef
21.
Office of Management and Budget. Standards for defining metropolitan and micropolitan statistical areas. Fed Regist. 2000;65:82228–38.
22.
U.S. Bureau of the Census. State and metropolitan area data book, 1997–1998. Washington, DC: US Bureau of the Census; 1998.
23.
Pierce T. Gen-X Junkie: ethnographic research with young white heroin users in Washington, DC. Subst Use Misuse. 1999;34:2095–114.PubMedCrossRef
24.
Wallace R, Wallace D. Socioeconomic determinants of health: community marginalization and the diffusion of disease and disorder in the United States. BMJ. 1997;314:1341–5.PubMed
25.
US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Treatment episode data set, 1992–2007 (concatenated). Data Collection Description; 2009.
26.
Beltrami J, Usman HR, Habarta N. HIV counseling and testing at CDC-funded sites, United States, Puerto Rico, and the U.S. Virgin Islands, 2005. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2010.
27.
Brady JE, Friedman SR, Cooper HLF, Flom PL, Tempalski B, Gostnell K. Estimating the prevalence of injection drug users in the US and in large US metropolitan areas from 1992–2002. J Urban Health. 2008;85:323–51.PubMedCrossRef
28.
Friedman SR, Tempalski B, Cooper HL, et al. Estimating numbers of injecting drug users in metropolitan areas for structural analyses of community vulnerability and for assessing relative degrees of service provision for injecting drug users. J Urban Health. 2004;81(3):377–400.PubMedCrossRef
29.
Holmberg S. The estimated prevalence and incidence of HIV in 96 large US metropolitan areas. Am J Public Health. 1996;86(5):642–54.PubMedCrossRef
30.
Census USBot. Population estimates program dataset: U.S. Bureau of the Census; 2009.
31.
Longford N. Random coefficient models. Oxford: Clarendon Press; 1993.
32.
Singer JD, Willett JB. Applied longitudinal data analysis: modeling change and event occurrence. New York: Oxford University Press; 2003.
33.
Verbeke G, Molenberghs G. Linear mixed models for longitudinal data. New York: Springer; 2000.
34.
Fitzmaurice GM, Ravichandran C. A primer in longitudinal data analysis. Circulation. 2008;118:2005–10.PubMedCrossRef
35.
Hedeker D. An introduction to growth modeling. In: Kaplan D, editor. Quantitative methodology for the social sciences. Thousand Oaks: Sage Publications; 2004.
36.
Pedhazur EJ, Schmelkin LP. Measurement, design and analysis: an integrated approach. Hillsdale: Lawrence Erlbaum Associates; 1991. p. 73–6.
37.
38.
U.S. Department of Health and Human Services, National Center for Health Statistics. Multiple cause of death file, 1992–2002 (computer file). U.S. Department of Health and Human Services, National Center for Health Statistics; 2004.
39.
Nunnally JC, Bernstein IH. Psychometric theory. 3rd ed. New York: McGraw Hill; 1994.
40.
Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: Erlbaum; 1988.
41.
42.
Tracy SW, Acker CJ, editors. Altering American consciousness: the history of alcohol and drug use in the United States. Amherst: University of Massachusetts; 2004. p. 1800–2000.
43.
The Washington Post/Kaiser Family Foundation/Harvard University. National survey on the public’s attitudes towards HIV/AIDS in the US and the World, July 2002. www.​kff.​org.
44.
45.
Firestone M, Fischer B. A qualitative exploration of prescription opioid injection among street-based drug users in Toronto: behaviours, preferences and drug availability. Harm Reduct J. 2008;5:30.PubMedCrossRef
46.
Latka M, Ahern J, Garfein RS, Ouellet L, Kerndt P, Morse P, et al. Prevalence, incidence, and correlates of chlamydia and gonorrhea among young adult injection drug users. J Subst Abuse. 2001;13:73–88.PubMedCrossRef
47.
Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155:645–53.PubMedCrossRef
48.
49.
CDC. Trends in HIV/AIDS diagnoses among men who have sex with men: 33 States, 2001–2006. MMWR. 2008;57:681–6.
50.
Hall HI, Byers RH, Ling Q, Espinoza L. Racial/ethnic and age disparities in HIV prevalence and disease progression among men who have sex with men in the United States. Am J Public Health. 2007;97(6):1060–6.PubMedCrossRef
51.
Hathazi, Lankenau, et al. Health status and service utilization among young injection drug users. American Public Health Association Annual Meeting, Washington, DC; November, 2007.
52.
53.
Tempalski B, Cleland CM, Pouget ER, Chatterjee S, Friedman SR. Persistence of low drug treatment coverage for injection drug users in large US metropolitan areas. Subst Abuse Treat Prev Policy. 2010;5:23.PubMedCrossRef
Metadata
Title
Changes in the Prevalence of Injection Drug Use Among Adolescents and Young Adults in Large U.S. Metropolitan Areas
Authors
Sudip Chatterjee
Barbara Tempalski
Enrique R. Pouget
Hannah L. F. Cooper
Charles M. Cleland
Samuel R. Friedman
Publication date
01-10-2011
Publisher
Springer US
Published in
AIDS and Behavior / Issue 7/2011
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI
https://doi.org/10.1007/s10461-011-9992-0

Other articles of this Issue 7/2011

AIDS and Behavior 7/2011 Go to the issue

Original Paper

Difficulty Accessing Syringes Mediates the Relationship Between Methamphetamine Use and Syringe Sharing Among Young Injection Drug Users

Original Paper

Depressive Symptoms and Food Insufficiency Among HIV-Infected Crack Users in Atlanta and Miami

Original Paper

Daily Assessment of Alcohol Consumption and Condom Use with Known and Casual Partners Among Young Female Bar Drinkers

Original Paper

Poverty, Hunger, Education, and Residential Status Impact Survival in HIV

Report

Incomplete Use of Condoms: The Importance of Sexual Arousal

Brief Report

Condom-Related Problems Among a Racially Diverse Sample of Young Men Who Have Sex with Men
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits